No. 50Articles
On this page

All reading for this session

· No. 050

Market analysis

PEPG Gapped 132% on Data From Six Patients. The Same Day, It Proposed a $125 Million Offering.

Abstract line chart of the stock's intraday path, drawn as layered ribbons without labels.
Abstract line chart of the stock's intraday path, drawn as layered ribbons without labels.

Public sources checked through November 11, 2026, at 5:13 p.m. ET.

On Nov. 10, PepGen released results from six patients in one cohort of an ongoing Phase 2 trial. PEPG opened at $5.54, up 132.01%, and closed at $4.61. The company also announced a proposed $125 million offering of common stock and pre-funded warrants that day. The clinical release gave the sample size. The preliminary offering document left two figures that matter for the share count blank: the offering price and the number of securities. Nov. 10 official recap · Clinical release · Preliminary prospectus supplement

What the 46.5% measured

The Nov. 10 release covered the 10 mg/kg cohort of FREEDOM2-DM1. At week 13, average RNA splicing correction in muscle was 46.5%, compared with 6.8% in the four-person pooled placebo group. Five of the six treated patients exceeded 20%. The placebo group drew from two dose cohorts, and the sample sizes matter as much as the averages. Nov. 10 clinical release

Splicing correction measures an effect on the biological process the drug targets. How quickly someone can release a clenched hand is a separate functional measure. PepGen also reported changes in hand-opening time and grip strength. The findings support further study. Six treated patients give little basis for estimating how often patients in a larger population would benefit, how long any benefit would last, or how often rare side effects would occur. Nov. 10 clinical release and functional measures

Launch, pricing and closing

The Nov. 10 announcement launched the proposed offering. The preliminary supplement already cited that day’s $4.61 closing price, while leaving the offer price, share and warrant counts, and net proceeds blank. Pre-funded warrants can take the place of some common shares in the offering and deliver common shares upon exercise. Both figures matter when counting how many shares the deal could add. As of 5:13 p.m. ET on Nov. 11, final pricing and closing remained unverified. Dividing the proposed $125 million by the stock’s closing price would give neither the final offering share count nor the number of shares issued. Nov. 10 launch announcement · Preliminary supplement · Company filing list

This article explains common concepts; examples are not trading recommendations.